Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 29, 2007

Filing Date
Filed February 20, 2008
Period End
December 29, 2007
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed February 20, 2008. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported net sales of $1,230.6 milliona for fiscal 2007 (ended December 29, 2007), up 16.3% from $1,058.4 million in 2006, driven by increased customer demand, higher pricing and the full-year impact of the Northwest Kinetics acquisition.

Operating income rose to $227.2 millionb from $188.2 million, with the operating margin improving to 18.5% from 17.8%. Net income was $154.4 million, or $2.25 diluted earnings per share, compared with a net loss of $55.8 million in 2006, which had included a $181.0 million loss from discontinued operations. Income from continuing operations was $157.6 million, or $2.29 diluted per share, versus $125.2 million, or $1.79, in 2006.

The Research Models and Services (RMS) segment, 46.9% of net sales, grew 12.1% to $577.2 millionc with an operating margin of 30.7%. The Preclinical Services (PCS) segment, 53.1% of net sales, grew 20.2% to $653.4 million with an operating margin of 15.8%. PCS backlog was approximately $393 million at year-end.

The company is in a substantial capacity expansion program, with $227.0 milliond of capital expenditures in 2007 and a planned $220 million to $240 million in 2008, including a new Nevada PCS facility, a China facility due to open in late 2008, and a Maryland RMS facility supporting a 10-year National Cancer Institute agreement. Balance sheet items include total debt of $510.0 million (including $350.0 million of 2.25% convertible senior notes due 2013), cash and cash equivalents of $225.4 million, and goodwill and other intangibles of $1.3 billion.

The company holds $38.2 million of auction rate securities, of which $14.2 million failed at auction in the first quarter of 2008. The company has not paid cash dividends in the past two years and does not intend to pay them in the foreseeable future, and it repurchased 199,200 shares in the fourth quarter under a $400.0 million authorization.

Key Highlights

  1. Net sales rose 16.3% to $1,230.6 million in 2007 from $1,058.4 million in 2006.
  2. Diluted earnings per share were $2.25 for net income and $2.29 from continuing operations, versus a 2006 net loss of $(0.80) per diluted share.
  3. Operating margin improved to 18.5% from 17.8%, with RMS operating margin up to 30.7% and PCS operating margin up to 15.8%.
  4. PCS segment net sales grew 20.2% to $653.4 million, with backlog of approximately $393 million at December 29, 2007.
  5. Operating cash flow was $288.4 million, up from $176.0 million in 2006, and capital expenditures were $227.0 million.
  6. Total debt was $510.0 million at year-end, including $350.0 million of 2.25% convertible senior notes due 2013.
  7. Approximately $38.2 million of auction rate securities were held at year-end, and $14.2 million failed at auction in the first quarter of 2008.

Frequently Asked Questions

  1. What drove the increase in Charles River's 2007 revenue?

    The filing attributes the $172.2 million sales increase primarily to increased customer demand, higher pricing and the full-year impact of the Northwest Kinetics Phase I clinical business acquired in late 2006. Favorable foreign currency translation added 2.9% to segment growth in both RMS and PCS.

  2. Why did the company report a net loss in 2006 but net income in 2007?

    The 2006 net loss of $(55.8) million was driven mainly by a $181.0 million loss from discontinued operations, which included a $129.2 million goodwill impairment and tax expense related to the sale of the Phase II-IV Clinical business. In 2007, the loss from discontinued operations was $3.1 million.

  3. How is Charles River spending on capacity, and what does it cost?

    The company spent $227.0 million on capital expenditures in 2007 and plans $220 million to $240 million in 2008. Projects include a new Nevada preclinical facility, expansions in Canada, Ohio and Scotland, a China facility due to open in late 2008, and a Maryland RMS facility. The filing warns that delays or cost increases could adversely affect results and operating margins, particularly in PCS.

  4. Does Charles River pay dividends, and how is it returning capital to shareholders?

    The company has not declared or paid cash dividends in the past two years and does not intend to pay them in the foreseeable future. It repurchased 199,200 shares in the fourth quarter of 2007 under a $400.0 million authorization, with approximately $96.4 million remaining.